Johnson & Johnson
Johnson & Johnson Announces Proposed Resolution of Ovarian Talc Litigation
Summary
Johnson & Johnson announced a proposed resolution of the ovarian talc litigation, conditioned on the participation of at least 95% of the remaining claims. The agreement includes a $5.5 billion commitment by the company, with the first payment of no more than $3 billion to be made in 2027. This resolution follows a favorable ruling by the MDL court regarding the inability of plaintiffs to prove specific causation. The company has previously settled about 95% of filed mesothelioma lawsuits, all State consumer protection claims, and all talc-supplier disputes. This resolution aims to bring finality to the 15-year litigation.
Profitelligence Alerts
Get alerts for JNJ
Be first to know when Johnson & Johnson files with the SEC.
Filing Categories
Advertisement
About Johnson & Johnson
Johnson & Johnson is a multinational corporation engaged in the research, development, production, and sale of a broad range of healthcare products. Primarily known for its pharmaceuticals, medical devices, and consumer health products, Johnson & Johnson has a significant presence in the global healthcare industry. It develops medications for a variety of fields such as immunology, oncology, neurology, infectious diseases, and vaccines. The company also produces a wide array of medical devices for surgery, orthopedics, and cardiovascular health. In addition to pharmaceuticals, Johnson & Johnson is renowned for its consumer health products, including baby care, skin and hair care, wound care, and over-the-counter pharmaceuticals, with well-recognized brands like Band-Aid, Tylenol, and Neutrogena. Operating globally, the corporation's extensive portfolio and commitment to healthcare innovation make it a pivotal player in the industry, ensuring it remains influential in addressing worldwide health challenges and advancing medical technology.
Official SEC Documents
Advertisement